Sotrovimab

DRUG17 trials

Sponsors

University of Oxford, Erin McCreary, Cambridge University Hospitals NHS Foundation Trust, Vir Biotechnology, Inc., GlaxoSmithKline

Conditions

COVID-19COVID-19 InfectionCovid19Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid NeoplasmSARS CoV 2 InfectionSevere Acute Respiratory Syndrome

Phase 1

A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian Participants

CompletedNCT04988152

Vir Biotechnology, Inc.Covid19

Start: 2021-07-06End: 2021-12-07Updated: 2024-06-07

Pharmacokinetics of Sotrovimab as Pre-exposure Prophylaxis for COVID-19 in Hematopoietic Stem Cell Transplant Recipients, COVIDMAB Study

TerminatedNCT05135650

Fred Hutchinson Cancer CenterCOVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm

Start: 2022-01-25End: 2023-01-10Updated: 2025-02-13

Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)

TerminatedNCT05280717

Vir Biotechnology, Inc.Covid19

Start: 2022-03-28End: 2023-11-06Updated: 2024-09-19

Phase 2

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V

CompletedNCT04870333

Cambridge University Hospitals NHS Foundation TrustCovid19

Start: 2021-02-19End: 2025-04-16Updated: 2025-06-20

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

RecruitingNCT05041907

University of OxfordCOVID-19

Start: 2021-09-30End: 2027-01-01Target: 3800Updated: 2026-02-19

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

TerminatedNCT05124210

GlaxoSmithKlineCOVID-19

Start: 2021-12-16End: 2023-06-14Updated: 2024-01-03

A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals

CompletedNCT05210101

Sophia Koo, M.D.SARS CoV 2 Infection

Start: 2022-02-07End: 2023-02-28Updated: 2024-08-15

Phase 3

Randomised Evaluation of COVID-19 Therapy

RecruitingNCT04381936

University of OxfordSevere Acute Respiratory Syndrome

Start: 2020-03-19End: 2036-06-30Target: 70000Updated: 2024-01-05

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

TerminatedNCT04913675

Vir Biotechnology, Inc.Covid19

Start: 2021-06-10End: 2023-03-24Updated: 2024-03-07

Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

TerminatedNCT04913675

Vir Biotechnology, Inc.Covid19

Start: 2021-06-10End: 2023-03-24Updated: 2024-03-07

Non-inferiority Trial on Monoclonal Antibodies in COVID-19

TerminatedNCT05205759

Azienda Ospedaliera Universitaria Integrata VeronaCOVID-19

Start: 2021-12-09End: 2022-04-05Updated: 2022-07-26

Non-inferiority Trial on Treatments in Early COVID-19

CompletedNCT05321394

Azienda Ospedaliera Universitaria Integrata VeronaCOVID-19

Start: 2022-03-07End: 2023-10-29Updated: 2023-11-07

Phase 4

UPMC OPTIMISE-C19 Trial, a COVID-19 Study

TerminatedNCT04790786

Erin McCrearyCovid19

Start: 2021-03-10End: 2022-06-16Updated: 2023-06-15

Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19

CompletedNCT05305651

GlaxoSmithKlineCOVID-19

Start: 2022-07-01End: 2023-07-17Updated: 2024-10-15

Unknown Phase

TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2

CompletedNCT05195060

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)COVID-19

Start: 2021-12-14End: 2025-09-01Updated: 2025-12-16

Sotrovimab Expanded Access Treatment Protocol (COVID-19)

Vir Biotechnology, Inc.Covid19

Updated: 2022-11-10

COVID-19 and Disease Progression to the Severe Form: a Study on the Use of Monoclonal Antibodies Against SARS-CoV-2

CompletedNCT05268601

University of Milano BicoccaCOVID-19

Start: 2021-10-14End: 2023-12-22Updated: 2025-03-30

Study on Sotrovimab and Its Impact on the Immune Response to COVID-19 Infection in Real-life in the UAE and Bahrain

Abu Dhabi Health Services CompanyCOVID-19

Start: 2022-05-12End: 2022-12-31Target: 20000Updated: 2022-06-01

Related Papers

Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg.

2025-12-01

LC-MS/MS Method Validation for Quantification of Nirmatrelvir in Human Plasma.

2025-11-17

Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.

2025-10-101 citations

Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2025-08-282 citations

Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2025-05-151 citations

Cost-effectiveness Analysis of Nirmatrelvir/Ritonavir for COVID-19 Among Individuals at High Risk: A Modeling Study

Open Forum Infectious Diseases2025-03-262 citations

Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.

2025-02-124 citations

Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V platform trial.

2025-02-11

Safety and tolerability of intramuscular sotrovimab administered at different injection sites: results from the Phase 1 COSMIC study

mAbs2025-01-291 citations

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV).

2025-01-183 citations

Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves.

2024-09-272 citations

Clinical trial results in context: comparison of baseline characteristics and outcomes of 38,510 RECOVERY trial participants versus a reference population of 346,271 people hospitalised with COVID-19 in England

Trials2024-06-294 citations

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).

2024-04-2410 citations

Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.

2024-01-317 citations

Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial.

2024-01-2218 citations

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.

2024-01-1518 citations

Dapagliflozin in patients with critical illness: rationale and design of the DEFENDER study.

2023-12-222 citations

Cardiac assessment and inflammatory markers in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV2 (PIMS-TS) treated with methylprednisolone versus intravenous immunoglobulins: 6-month follow-up outcomes of the randomised controlled Swissped RECOVERY trial.

2023-12-065 citations

497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial

Open Forum Infectious Diseases2023-11-27

Pharmacokinetics, Safety, and Tolerability of Anti-SARS-CoV-2 Monoclonal Antibody, Sotrovimab, Delivered Intravenously or Intramuscularly in Japanese and Caucasian Healthy Volunteers.

2023-11-133 citations

39 more papers not shown